AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	838	81-13-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dexpanthenol (+)-panthenol bepanthen D-Panthenol	The alcohol of pantothenic acid Molecular weight: 205.25 Formula: C9H19NO4 CLOGP: -1.65 LIPINSKI: 0 HAC: 5 HDO: 4 TPSA: 89.79 ALOGS: -0.23 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dexpanthenol
(+)-panthenol
bepanthen
D-Panthenol

The alcohol of pantothenic acid

Molecular weight: 205.25
Formula: C9H19NO4
CLOGP: -1.65
LIPINSKI: 0
HAC: 5
HDO: 4
TPSA: 89.79
ALOGS: -0.23
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,MAP2K6,MAP3K21,MAP3K7,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1	36
kinase-selectivity-class	ACVRL1,AXL,BRAF,CDK1,CDK2,CDK4,CDK6,CDK9,CHUK,DYRK1A,EPHB4,GRK2,MAP2K6,MAP3K21,PDK1,PDK2,TEK,TGFBR1	18
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Feb. 20, 1953	FDA	HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumonia aspiration	156.61	14.09	84	11220	40856	90576287
Gastrooesophageal reflux disease	115.34	14.09	122	11182	166215	90450928
Coma	101.36	14.09	79	11225	72553	90544590
Toxic epidermal necrolysis	84.80	14.09	52	11252	32476	90584667
Female genital tract fistula	80.69	14.09	41	11263	17827	90599316
Chronic sinusitis	74.98	14.09	43	11261	23759	90593384
Epidermal necrosis	73.21	14.09	22	11282	2339	90614804
Vaginal flatulence	68.99	14.09	33	11271	12605	90604538
Proctitis	63.09	14.09	33	11271	15226	90601917
Radiculopathy	59.81	14.09	34	11270	18471	90598672
Vaginal discharge	55.58	14.09	33	11271	19431	90597712
Epilepsy	51.13	14.09	57	11247	82149	90534994
Paraesthesia oral	49.79	14.09	37	11267	31622	90585521
Somnolence	46.50	14.09	89	11215	208995	90408148
Oral candidiasis	46.07	14.09	37	11267	35418	90581725
Facet joint syndrome	44.45	14.09	58	11246	98331	90518812
Colitis	44.36	14.09	49	11255	69893	90547250
Procedural pain	43.74	14.09	35	11269	33325	90583818
Macular degeneration	41.80	14.09	36	11268	37934	90579209
Lip dry	37.29	14.09	54	11250	100901	90516242
Osteoarthritis	37.14	14.09	78	11226	195652	90421491
Bursitis	36.88	14.09	62	11242	131592	90485551
Nail disorder	36.79	14.09	41	11263	59026	90558117
Tumour pain	35.42	14.09	12	11292	1875	90615268
Rash papular	34.74	14.09	25	11279	20330	90596813
Frequent bowel movements	34.57	14.09	39	11265	56896	90560247
Colitis ulcerative	32.77	14.09	39	11265	60227	90556916
Obesity	32.68	14.09	52	11252	105455	90511688
Wound infection	32.35	14.09	52	11252	106350	90510793
Pulmonary vein occlusion	31.31	14.09	6	11298	90	90617053
Breast cancer stage III	30.93	14.09	45	11259	84402	90532741
Plasma cells increased	30.55	14.09	6	11298	103	90617040
Underdose	29.44	14.09	35	11269	53982	90563161
Intestinal haemorrhage	28.57	14.09	13	11291	4434	90612709
Live birth	24.51	14.09	39	11265	79068	90538075
Rectal haemorrhage	23.20	14.09	39	11265	82705	90534438
Inflammation	22.79	14.09	61	11243	178531	90438612
Haematochezia	22.02	14.09	35	11269	70878	90546265
Drug interaction	21.91	14.09	4	11300	276449	90340694
C-reactive protein	21.67	14.09	23	11281	31344	90585799
Musculoskeletal pain	21.36	14.09	58	11246	171193	90445950
Anterior segment ischaemia	21.34	14.09	4	11300	53	90617090
Toxicity to various agents	21.09	14.09	5	11299	287841	90329302
Optic nerve disorder	19.75	14.09	7	11297	1251	90615892
Stomatitis	19.69	14.09	77	11227	274621	90342522
Peripheral venous disease	18.97	14.09	36	11268	83885	90533258
Wheezing	18.94	14.09	69	11235	238011	90379132
Liver injury	18.57	14.09	55	11249	170512	90446631
Death	18.28	14.09	18	11286	456533	90160610
Stevens-Johnson syndrome	17.62	14.09	20	11284	29356	90587787
Muscle injury	17.39	14.09	55	11249	176599	90440544
Psoriatic arthropathy	17.18	14.09	65	11239	228270	90388873
Sinusitis fungal	16.72	14.09	7	11297	1957	90615186
Blepharospasm	16.71	14.09	27	11277	55418	90561725
Drug ineffective	16.67	14.09	103	11201	1384195	89232948
Product dose omission issue	16.30	14.09	8	11296	291679	90325464
Taste disorder	15.93	14.09	28	11276	61518	90555625
Fibromyalgia	15.75	14.09	59	11245	206210	90410933
Streptococcal infection	14.84	14.09	10	11294	7323	90609820
Dyspepsia	14.56	14.09	56	11248	198104	90419039

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	48.15	21.06	61	3489	151185	42466600
Foetal malformation	47.98	21.06	9	3541	184	42617601
Appendicolith	41.72	21.06	21	3529	13435	42604350
Hyperphosphataemia	39.45	21.06	20	3530	12984	42604801
Dehiscence	37.14	21.06	9	3541	637	42617148
Febrile bone marrow aplasia	34.85	21.06	17	3533	10164	42607621
Trisomy 18	34.53	21.06	9	3541	856	42616929
Appendicitis	33.35	21.06	21	3529	20592	42597193
Myasthenia gravis	32.71	21.06	19	3531	16118	42601667
Analgesic therapy	32.06	21.06	14	3536	6510	42611275
Blood phosphorus increased	31.52	21.06	17	3533	12508	42605277
Swelling	31.10	21.06	30	3520	54855	42562930
Generalised oedema	30.94	21.06	18	3532	15318	42602467
Dry mouth	30.89	21.06	26	3524	39853	42577932
Face oedema	30.14	21.06	17	3533	13649	42604136
Drug therapy	29.12	21.06	13	3537	6367	42611418
Ventricular fibrillation	28.33	21.06	22	3528	30101	42587684
Hypophosphataemia	28.16	21.06	19	3531	20926	42596859
Sleep disorder therapy	28.15	21.06	13	3537	6881	42610904
Anaemia	27.26	21.06	67	3483	280211	42337574
Incorrect route of product administration	25.61	21.06	19	3531	24286	42593499
Blood uric acid increased	25.55	21.06	16	3534	15531	42602254
Iron deficiency	25.04	21.06	14	3536	11047	42606738
Neuralgia	24.70	21.06	19	3531	25628	42592157
Pulmonary embolism	24.31	21.06	39	3511	119573	42498212
Ascites	23.14	21.06	26	3524	56652	42561133
Cardiogenic shock	23.10	21.06	21	3529	35619	42582166
Bacteroides infection	21.14	21.06	8	3542	2579	42615206

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Female genital tract fistula	81.73	15.28	41	14482	16478	110558298
Gastrooesophageal reflux disease	81.51	15.28	109	14414	179867	110394909
Chronic sinusitis	70.82	15.28	43	14480	25041	110549735
Vaginal flatulence	68.61	15.28	33	14490	12111	110562665
Pneumonia aspiration	66.89	15.28	67	14456	81166	110493610
Epidermal necrosis	66.55	15.28	22	14501	3028	110571748
Toxic epidermal necrolysis	66.52	15.28	57	14466	56670	110518106
Proctitis	60.99	15.28	34	14489	16893	110557883
Radiculopathy	59.40	15.28	35	14488	19301	110555475
Macular degeneration	58.26	15.28	36	14487	21623	110553153
Vaginal discharge	56.55	15.28	33	14490	17875	110556901
Facet joint syndrome	50.62	15.28	63	14460	96765	110478011
Epilepsy	50.48	15.28	64	14459	100145	110474631
Osteoarthritis	46.66	15.28	85	14438	182538	110392238
Paraesthesia oral	46.06	15.28	37	14486	33634	110541142
Lip dry	42.81	15.28	59	14464	100024	110474752
Bursitis	41.80	15.28	67	14456	129851	110444925
Procedural pain	40.20	15.28	35	14488	35530	110539246
Nail disorder	39.13	15.28	43	14480	57892	110516884
Oral candidiasis	38.84	15.28	38	14485	44722	110530054
Wound infection	38.48	15.28	55	14468	96410	110478366
Coma	38.21	15.28	61	14462	117808	110456968
Toxicity to various agents	36.68	15.28	9	14514	480546	110094230
Breast cancer stage III	35.90	15.28	48	14475	79069	110495707
Obesity	35.83	15.28	58	14465	113293	110461483
Somnolence	34.14	15.28	101	14422	297348	110277428
Appendicolith	34.10	15.28	22	14501	14233	110560543
Tumour pain	32.99	15.28	13	14510	2954	110571822
Incorrect route of product administration	32.39	15.28	41	14482	64020	110510756
Colitis	31.86	15.28	52	14471	102271	110472505
Muscle injury	31.57	15.28	62	14461	140745	110434031
Live birth	31.28	15.28	42	14481	69442	110505334
Stomatitis	30.28	15.28	91	14432	270151	110304625
Plasma cells increased	29.19	15.28	6	14517	124	110574652
Hyperphosphataemia	29.01	15.28	21	14502	16360	110558416
Pulmonary vein occlusion	28.92	15.28	6	14517	130	110574646
Psoriatic arthropathy	27.70	15.28	72	14451	196689	110378087
Analgesic therapy	27.25	15.28	15	14508	7269	110567507
Dehiscence	27.20	15.28	8	14515	750	110574026
Liver injury	26.47	15.28	60	14463	150353	110424423
Frequent bowel movements	26	15.28	39	14484	71351	110503425
Fibromyalgia	25.57	15.28	64	14459	170845	110403931
Inflammation	25.46	15.28	69	14454	193169	110381607
Swelling	25.21	15.28	102	14421	350939	110223837
Duodenal ulcer perforation	24.98	15.28	65	14458	177635	110397141
Rash papular	24.98	15.28	24	14499	27615	110547161
Drug therapy	24.52	15.28	14	14509	7277	110567499
Sleep disorder therapy	24.20	15.28	14	14509	7457	110567319
Musculoskeletal pain	23.76	15.28	65	14458	182958	110391818
Lower respiratory tract infection	23.68	15.28	78	14445	243028	110331748
Underdose	23.55	15.28	35	14488	63519	110511257
General physical health deterioration	23.31	15.28	114	14409	425181	110149595
C-reactive protein	23.10	15.28	24	14499	30307	110544469
Anaemia	22.78	15.28	136	14387	546950	110027826
Blood phosphorus increased	22.44	15.28	18	14505	16322	110558454
Colitis ulcerative	22.32	15.28	38	14485	77325	110497451
Myasthenia gravis	21.98	15.28	20	14503	21491	110553285
Intestinal haemorrhage	21.79	15.28	13	14510	7328	110567448
Blood cholesterol increased	21.42	15.28	63	14460	184722	110390054
Dry mouth	21.14	15.28	66	14457	199882	110374894
Anterior segment ischaemia	21.13	15.28	4	14519	53	110574723
Drug ineffective	20.92	15.28	116	14407	1520424	109054352
Drug interaction	20.81	15.28	21	14502	500162	110074614
Appendicitis	20.74	15.28	22	14501	28442	110546334
Peripheral venous disease	20.02	15.28	38	14485	84079	110490697
Wheezing	19.80	15.28	76	14447	255154	110319622
Pericarditis	18.45	15.28	67	14456	219047	110355729
Hypophosphataemia	17.99	15.28	22	14501	33160	110541616
Stevens-Johnson syndrome	17.62	15.28	26	14497	46875	110527901
Dyspepsia	17.46	15.28	60	14463	190905	110383871
Optic nerve disorder	17.33	15.28	7	14516	1696	110573080
Abdominal pain	17.33	15.28	121	14402	512868	110061908
Breast cancer metastatic	16.82	15.28	13	14510	11168	110563608
Pemphigus	16.72	15.28	64	14459	214506	110360270
Bacteroides infection	16.69	15.28	8	14515	2911	110571865
Helicobacter infection	16.50	15.28	57	14466	181820	110392956
Product dose omission issue	16.49	15.28	11	14512	321771	110253005
Blood uric acid increased	16.33	15.28	17	14506	21512	110553264
Rectal haemorrhage	15.99	15.28	43	14480	119790	110454986
Blepharospasm	15.89	15.28	27	14496	54824	110519952
Ventricular fibrillation	15.66	15.28	23	14500	41290	110533486

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A11HA30	ALIMENTARY TRACT AND METABOLISM VITAMINS OTHER PLAIN VITAMIN PREPARATIONS Other plain vitamin preparations
ATC	D03AX03	DERMATOLOGICALS PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS CICATRIZANTS Other cicatrizants
ATC	S01XA12	SENSORY ORGANS OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS Other ophthalmologicals
CHEBI has role	CHEBI:38323	cholinergic drugs
CHEBI has role	CHEBI:50188	provitamins

Related Drugs by ATC class:

A11HA Other plain vitamin preparations 10 drugs

biotin calcium pantothenate inositol nicotinamide pantethine pyridoxal phosphate pyridoxine riboflavin tocofersolan Vitamin E

D03AX Other cicatrizants 9 drugs

becaplermin beremagene geperpavec calcium pantothenate crilanomer enoxolone hyaluronic acid sodium chlorite trafermin trolamine

S01XA Other ophthalmologicals 24 drugs

acetylcysteine alteplase alum ascorbic acid avacincaptad pegol cenegermin ciclosporin diquafosol ethylmorphine guaiazulen heparin inosine show all 24 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Eczema	indication	43116000
Toxicodendron radicans	indication	52352005
Paralytic ileus	indication	55525008	DOID:8442
Diaper rash	indication	91487003
Disorder of skin	indication	95320005	DOID:37
Contact dermatitis due to poison oak	indication	200824008
Gastroparesis	indication	235675006
Arthropod bite wound	indication	409985002
Paralytic Ileus Prevention	indication
Chafing of skin	off-label use	238474002
Eruption of skin	off-label use	271807003	DOID:0050486
Skin irritation	off-label use	367466007
Itching of skin	off-label use	418363000
Hemophilia	contraindication	90935002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.71	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML	MULTIPLE VITAMINS INJECTION ADULT	APOTEX	A210672	April 9, 2026	RX	SOLUTION	INTRAVENOUS	Dec. 1, 2026	COMPETITIVE GENERIC THERAPY
80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	MULTIPLE VITAMINS INJECTION PEDIATRIC	APOTEX	A210671	April 21, 2026	RX	INJECTABLE	INTRAVENOUS	Dec. 21, 2026	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

None

External reference:

ID	Source
4020828	VUID
N0000146036	NUI
22701	RXNORM
4017657	VANDF
4020828	VANDF
C0057610	UMLSCUI
CHEBI:27373	CHEBI
CHEMBL1200979	ChEMBL_ID
DB09357	DRUGBANK_ID
131204	PUBCHEM_CID
C007288	MESH_SUPPLEMENTAL_RECORD_UI
1023	INN_ID
1O6C93RI7Z	UNII
1536	MMSL
4558	MMSL
d01001	MMSL
001696	NDDF
126226000	SNOMEDCT_US
404842009	SNOMEDCT_US
1O6C93RI7Z	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
MIRACLE STEMCELL ALL-IN-ONE	HUMAN OTC DRUG LABEL	2	24765-001	SHAMPOO	0.20 g	TOPICAL	unapproved drug other	7 sections
HASOL Anagen Hair Tonic	HUMAN OTC DRUG LABEL	3	51270-122	LIQUID	0.00 1	TOPICAL	unapproved drug other	8 sections
HASOL Anagen Scalp	HUMAN OTC DRUG LABEL	3	51270-123	SHAMPOO	0.00 1	TOPICAL	unapproved drug other	8 sections
HASOL Anti Hair Loss	HUMAN OTC DRUG LABEL	3	51270-124	SHAMPOO	0.00 1	TOPICAL	unapproved drug other	8 sections
HASOL Vital For Hair-Loss Tonic	HUMAN OTC DRUG LABEL	3	51270-125	LIQUID	0.00 1	TOPICAL	unapproved drug other	8 sections
Adult Infuvite Multiple Vitamins	HUMAN PRESCRIPTION DRUG LABEL	13	54643-9007	INJECTION, SOLUTION	15 mg	INTRAVENOUS	NDA	20 sections
Adult Infuvite Multiple Vitamins	HUMAN PRESCRIPTION DRUG LABEL	13	54643-9015	INJECTION, SOLUTION	15 mg	INTRAVENOUS	NDA	20 sections
Pediatric Infuvite Multiple Vitamins	HUMAN PRESCRIPTION DRUG LABEL	13	54643-9023	INJECTION, SOLUTION	5 mg	INTRAVENOUS	NDA	19 sections
Pediatric Infuvite Multiple Vitamins	HUMAN PRESCRIPTION DRUG LABEL	13	54643-9023	INJECTION, SOLUTION	5 mg	INTRAVENOUS	NDA	19 sections
Vitamin B Complex	HUMAN PRESCRIPTION DRUG LABEL	5	67457-146	INJECTION	2 mg	INTRAVENOUS	Unapproved drug other	9 sections
NDM SCALP	HUMAN OTC DRUG LABEL	4	69288-001	SHAMPOO	1.40 g	TOPICAL	unapproved drug other	11 sections
YOZUM WELL BEING HAIR COLOR	HUMAN OTC DRUG LABEL	1	69525-2001	LIQUID	0.20 g	TOPICAL	OTC monograph not final	7 sections
Notamo Hair Tonic	HUMAN OTC DRUG LABEL	2	69709-102	LIQUID	0.20 1	TOPICAL	unapproved drug other	8 sections
B-Combo	HUMAN PRESCRIPTION DRUG LABEL	6	70104-110	INJECTION	1 mg	INTRAMUSCULAR	unapproved drug other	1 sections
Lipovite	HUMAN PRESCRIPTION DRUG LABEL	13	70104-128	INJECTION	1 mg	INTRAMUSCULAR	unapproved drug other	1 sections
Therapytion Hair Tonic	HUMAN OTC DRUG LABEL	2	70477-101	LIQUID	0.00 1	TOPICAL	unapproved drug other	8 sections
BABYSONS	HUMAN OTC DRUG LABEL	1	73519-001	OINTMENT	50 mg	TOPICAL	unapproved drug other	11 sections
Yakkongmo scalp deep cleansingshampoo	HUMAN OTC DRUG LABEL	4	73540-001	SHAMPOO	0.50 g	TOPICAL	unapproved drug other	7 sections
Yakkongmo hair serum tonic	HUMAN OTC DRUG LABEL	3	73540-002	LIQUID	0.20 g	TOPICAL	unapproved drug other	7 sections
Yakkongmo treatment	HUMAN OTC DRUG LABEL	3	73540-003	LIQUID	0.50 g	TOPICAL	unapproved drug other	7 sections
CRAZYSKIN BEERS	HUMAN OTC DRUG LABEL	3	73643-0001	SHAMPOO	0.20 g	TOPICAL	unapproved drug other	7 sections
CRAZYSKIN BEERS PREMIUM	HUMAN OTC DRUG LABEL	3	73643-0002	SHAMPOO	0.20 g	TOPICAL	unapproved drug other	7 sections
W.SKIN ANTI HAIR LOSS	HUMAN OTC DRUG LABEL	3	74997-0016	SHAMPOO	0.50 g	TOPICAL	unapproved drug other	7 sections
The Fact Hair Care Scalp Booster Ampoule	HUMAN OTC DRUG LABEL	3	77049-0013	LIQUID	0.20 g	TOPICAL	unapproved drug other	7 sections
BLACK REPAIR HAIR BOOSTING TONIC	HUMAN OTC DRUG LABEL	3	79593-0005	LIQUID	0.20 g	TOPICAL	unapproved drug other	7 sections
Derma Hand Repair	HUMAN OTC DRUG LABEL	2	82160-450	CREAM	22.50 mg	TOPICAL	unapproved drug other	13 sections
Derma Charcoal Mask	HUMAN OTC DRUG LABEL	3	82160-672	GEL	15 mg	TOPICAL	unapproved drug other	17 sections
CH6 Perfumed Aloforthya Peony and the sunset	HUMAN OTC DRUG LABEL	3	82916-050	SHAMPOO	0.20 g	TOPICAL	unapproved drug other	10 sections
MONPURIEL Daily all in one ample	HUMAN OTC DRUG LABEL	3	83472-311	LIQUID	0.22 g	TOPICAL	unapproved drug other	11 sections
MONPURIEL Hair loss care-shampoo	HUMAN OTC DRUG LABEL	3	83472-411	SHAMPOO	0.22 g	TOPICAL	unapproved drug other	11 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

dexpanthenol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: